Who is sponsoring NCT06140420?

NCT06140420 is sponsored by Texas Tech University.

What drugs are being tested in NCT06140420?

Interventions in NCT06140420: Naltrexone Oral Product, Placebo.

What condition does NCT06140420 study?

NCT06140420 studies Naltrexone HCl 50 MG Oral Tablet, Placebo.

Is NCT06140420 still recruiting?

NCT06140420 is currently terminated. Last updated 8 June 2025.

Last reviewed 2025-06-08 · How we verify

NCT06140420: NPGD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Naltrexone for Prolonged Grief Disorder

Terminated Phase 4 Last updated 8 June 2025

What this trial tests

Phase 4 trial testing Naltrexone Oral Product in Naltrexone HCl 50 MG Oral Tablet in 7 participants. Terminated before completion.

Timeline

1 August 2023

Primary endpoint
1 February 2025

1 February 2025

Quick facts

Lead sponsor	Texas Tech University
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	7
Start date	1 August 2023
Primary completion	1 February 2025
Estimated completion	1 February 2025
Sites	1 location across United States

Drugs / interventions tested

Naltrexone Oral Product — full drug profile →
Placebo

Conditions studied

Naltrexone HCl 50 MG Oral Tablet — all drugs for Naltrexone HCl 50 MG Oral Tablet →
Placebo — all drugs for Placebo →

Sponsor

Texas Tech University

Who can join

Adults 18 to 120, any sex, with Naltrexone HCl 50 MG Oral Tablet or Placebo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Texas Tech University trials

Trials by the same sponsor.

NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
NCT07239609 — ACT for Individuals With MNCD and Their Care Partners · Phase 1 · not yet recruiting
NCT06919536 — Controlled Feeding With 24 Hour Recall · completed
NCT06055322 — Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD · NA · recruiting
NCT06865196 — Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06140420 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas Tech University
Last refreshed: 8 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06140420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing